TY  - JOUR
TI  - Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center
AB  - Introduction: Pulmonary thromboembolism (PTE) is a life-threatening disease, with substantial treatment-related complications, difficult follow-up, treatment compliance, and high costs. This study aimed to assess treatment costs with various maintenance therapy regimens, complications, and patient adherence to treatment over a one-year follow-up period. Materials and Methods: This observational, prospective study included 142 patients with PTE who received maintenance anticoagulation therapy between November 2020 and March 2023. The patients were observed at three-month intervals for a year. Possible treatment-related complications, recurrence, mortality, and treatment costs were recorded. Results: Our results showed that there was no significant difference in bleeding risk based on the drugs used for initial or maintenance treatment. In mainte- nance therapy, low-molecular-weight heparin (LMWH), warfarin, and direct oral anticoagulant (DOAC) treatment regimens had similar treatment adher- ence and comparable efficacy and safety in terms of recurrence and bleeding (p> 0.05). Four patients (2.8%) were diagnosed with chronic thromboem- bolic disease. The one-year mortality rate was 24.6% (n= 35), of which 82.9% (n= 29) occurred within the first three months. Hospital mortality rates with the different maintenance therapies were 8.8% in the LMWH group, 5.7% in the warfarin group, and 3.2% in the DOAC group. The annual cost of using LMWH was higher than that of rivaroxaban, apixaban, and warfarin (p< 0.001) while there was no significant cost difference between DOACs and warfarin (p> 0.05). Conclusion: In our study, the LMWH, warfarin, and DOAC treatment regimens had similar efficacy, safety, and patient compliance. In terms of cost, LMWH was the costliest while DOAC and warfarin were similar.
AU  - Ergül, Ersin
AU  - Yilmazel Ucar, Elif
AU  - Araz, Omer
AU  - Aksakal, Alperen
AU  - Kerget, Bugra
AU  - SAGLAM, Leyla
DO  - 10.5578/tt.20239607
PY  - 2023
JO  - Tüberküloz ve Toraks
VL  - 71
IS  - 4
SN  - 0494-1373
SP  - 390
EP  - 399
DB  - TRDizin
UR  - http://search/yayin/detay/1213730
ER  -